First authors of the article -Jeff Weitz/Hamilton Health Sciences; Robert Harrington/Weill Cornell Medicine
May 2, 2026, 13:10
Targeting FXIa As a Safer Anticoagulant Target Than FXa in LIBREXIA Trial – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by et al, adding:
”Rationale for the Milvexian Dosing in the Phase 3 LIBREXIA Program
This narrative review details the pharmacological rationale for targeting FXIa as a safer anticoagulant target than FXa, and outlines how phase 2 findings informed milvexian dosing regimens across three phase 3 LIBREXIA trials enrolling approximately 50,000 patients with AF, ACS, or ischemic stroke.”
Title: Rationale for the Milvexian Dosing in the Phase 3 LIBREXIA Program
Authors: Jeff Weitz, Robert Harrington on behalf of the LIBREXIA Program Executive Council
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 25, 2026, 05:26Paola Mendez Hiraldo: Glenn Ruperto’s Stroke Recovery and the Power of Team-Based Care
-
Jun 25, 2026, 05:19Steven Bell: Lessons in Rapid Stroke Care from Vall d’Hebron University Hospital
-
Jun 25, 2026, 04:48Brianne Martin: Stroke Recovery Is More Than Medical Appointments
-
Jun 24, 2026, 22:30The Clinical Impact of Anaphylaxis-Associated Coagulopathy – JTH
-
Jun 24, 2026, 21:08Martin Haluzík: Semaglutide as a Strategy for Primary Prevention of Cerebrovascular Disease in RA
-
Jun 24, 2026, 19:43New ASH/ISTH 2026 Guidelines for Pediatric Anticoagulant Prophylaxis of VTE Are Now Live – Blood Journals Portfolio
-
Jun 24, 2026, 18:36Maryam Sardar: Timely Anticoagulation in SMV Thrombosis Complicating Acute Pancreatitis
-
Jun 24, 2026, 17:36Paul Whiteley: Neurodevelopmental and Autism Risks in Fetal and Neonatal Alloimmune Thrombocytopenia
-
Jun 24, 2026, 17:22Kavitha Dev: A Low Platelet Count Isn’t Always Critical, But It Should Never Be Ignored